Changeflow GovPing Securities & Markets Apimeds Pharmaceuticals 8-K Delisting Notice, M...
Priority review Notice Added Final

Apimeds Pharmaceuticals 8-K Delisting Notice, Matawan, NJ, 22nd Apr

Favicon for changeflow.com EDGAR: Delisting Notices (8-K 3.01)
Published
Detected
Email

Summary

Apimeds Pharmaceuticals, a pharmaceutical company based in Matawan, NJ, filed an 8-K current report with the SEC on April 22, providing formal notice of delisting. The filing was submitted under Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard), which triggers the exchange's delisting procedures. Public shareholders and investors should monitor the company's continued disclosure obligations during the delisting process.

Published by SEC on sec.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EDGAR: Delisting Notices (8-K 3.01) for new securities & markets regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 30 changes logged to date.

What changed

Apimeds Pharmaceuticals filed an 8-K current report with the SEC providing notice of delisting under Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard). The filing was made on April 22, 2026, from the company's headquarters in Matawan, NJ.

Public shareholders and investors tracking Apimeds should monitor for subsequent 8-K filings as the delisting process unfolds, including any notification from the applicable stock exchange regarding suspension of trading and final delisting dates.

Named provisions

Item 3.01

Get daily alerts for EDGAR: Delisting Notices (8-K 3.01)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from SEC.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
SEC
Published
April 22nd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Public companies Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Delisting procedures Exchange compliance
Geographic scope
United States US

Taxonomy

Primary area
Securities
Operational domain
Compliance
Topics
Healthcare

Get alerts for this source

We'll email you when EDGAR: Delisting Notices (8-K 3.01) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!